Phase II evaluation of pyrazofurin in patients with carcinoma of the lung

Richard J. Gralla, V. E. Currie, R. E. Wittes, R. B. Golbey, C. W. Young

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.

Original languageEnglish (US)
Pages (from-to)451-452
Number of pages2
JournalCancer Treatment Reports
Volume62
Issue number3
StatePublished - 1978
Externally publishedYes

Fingerprint

pyrazofurin
Carcinoma
Lung
Lung Neoplasms
Mucositis
Survival
Group Psychotherapy
Anemia
Appointments and Schedules
Outpatients
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gralla, R. J., Currie, V. E., Wittes, R. E., Golbey, R. B., & Young, C. W. (1978). Phase II evaluation of pyrazofurin in patients with carcinoma of the lung. Cancer Treatment Reports, 62(3), 451-452.

Phase II evaluation of pyrazofurin in patients with carcinoma of the lung. / Gralla, Richard J.; Currie, V. E.; Wittes, R. E.; Golbey, R. B.; Young, C. W.

In: Cancer Treatment Reports, Vol. 62, No. 3, 1978, p. 451-452.

Research output: Contribution to journalArticle

Gralla, RJ, Currie, VE, Wittes, RE, Golbey, RB & Young, CW 1978, 'Phase II evaluation of pyrazofurin in patients with carcinoma of the lung', Cancer Treatment Reports, vol. 62, no. 3, pp. 451-452.
Gralla, Richard J. ; Currie, V. E. ; Wittes, R. E. ; Golbey, R. B. ; Young, C. W. / Phase II evaluation of pyrazofurin in patients with carcinoma of the lung. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 3. pp. 451-452.
@article{671b5df4e5044469949bab39736ebc4a,
title = "Phase II evaluation of pyrazofurin in patients with carcinoma of the lung",
abstract = "Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.",
author = "Gralla, {Richard J.} and Currie, {V. E.} and Wittes, {R. E.} and Golbey, {R. B.} and Young, {C. W.}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "451--452",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase II evaluation of pyrazofurin in patients with carcinoma of the lung

AU - Gralla, Richard J.

AU - Currie, V. E.

AU - Wittes, R. E.

AU - Golbey, R. B.

AU - Young, C. W.

PY - 1978

Y1 - 1978

N2 - Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.

AB - Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0018193162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018193162&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 451

EP - 452

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -